Our results confirm our previous finding that on longitudinal analysis, impaired olfaction, cognitive impairment, and the motor prodromal signs and symptoms of idiopathic PD are more pronounced among GBA1 mutation carriers.11 Currently, clinical trials of a number neuroprotective compounds targeting the GBA pathway are ongoing. Here, GBA1 is linked to Cognitive impairment.